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Dear Editor and Referees, 
 
We would like you to consider the revised version of our manuscript ID 2017-BJP-1448-RP 
entitled "Stable Isotope-Labelled Morphine to Study In Vivo Central and Peripheral 
Morphine Glucuronidation and Brain Transport in Tolerant Mice" for publication in Brit. J. 
Pharmacology. 
We thank you for your insightful comments and recommendations, which clearly led us to 
improve the content and clarity of the manuscript. We have addressed your concerns as described 
below. We hope this revised version is acceptable for publication. 
 
Thank you for your time and attention, 
 
Yannick GOUMON 
 
 
 
 
Editor 
Comments to the Author: 
The manuscript 2017-BJP-1448-RP by Ivan Weinsanto and co-workers has been reviewed by 
2 experts and one Editor. The manuscript aimed to study morphine metabolism following chronic 
administration using  a deuterated analogue of morphine. 
Although this is an interesting paper, it shows some significant limitations i) first in terms of 
novelty (see comments from reviewer 2) ii) secondly in terms of mimicking the clinical features fo 
morphine induced tolerance to its analgesic properties (see comments from reviewer 1) and iii) 
thirdly the pharmacological properties of the  deuterated analogue of morphine are not 
documented, although one would anticipate similar properties as the native drug (ie morphine). 
 
Answer:  
i) First regarding novelty (see comments from reviewer 2):  
 
We fully agree with this criticism, and we thank the reviewer 2 for providing arguments that 
have changed our point of view. These insightful comments and recommendations led us to 
greatly improve the content and clarity of the manuscript. Notably, we have expanded our 
introduction, discussion and bibliography on metabolic studies using stable isotope-labelled 
compounds (see answers to Reviewer 2). 
 
ii) Secondly in terms of mimicking the clinical features of morphine-induced tolerance to its 
analgesic properties (see comments from reviewer 1):  
 
In the literature, a major portion of morphine analgesic tolerance studies involves repeated 
discontinuous (multiple injections) rather than continuous (pellets) administrations of morphine 
(i.e., 2259 articles vs 269 articles, respectively; source: Web of Science). We now provide in the 
text the articles of Ueda & coll (cited 114 times; (Ueda, Yamaguchi, Tokuyama, Inoue, Nishi & 
Takeshima, 1997)) and Elhabazi & coll. published in JoVE in 2014 (Elhabazi, Ayachi, Ilien & 
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Simonin, 2014). In our experiments, a typical decrease of morphine-induced analgesia (please 
see new Fig. 2b) attests unambiguously that tolerance was established by day 9. 
 
iii)  Thirdly the pharmacological properties of the deuterated analogue of morphine are not 
documented:  
 
Up till now, only Elison and coll. have described a difference of analgesic and toxicity 
effects between morphine and d3-morphine (Elison, Rapoport, Laursen & Elliott, 1961). Our 
present article focuses on morphine and d3-morphine metabolism in mice, and we observed a 
slight reduction of analgesic potency when we used a 15%/85% d3-morphine/morphine mixture 
compared to 100% morphine (Fig. 2b). A new ongoing study performed in our laboratory is 
currently comparing the pharmacological properties of d3-morphine and morphine using 
behavioural tests and binding assays. D3-morphine appears to be 50% less analgesic than 
morphine (which is in agreement with data reported by Elison et al. (Elison, Rapoport, Laursen 
& Elliott, 1961)) without any difference regarding affinity for the mu opioid receptor (binding 
assay). We will complete our next study with G-protein activation and cAMP production assays, 
as well as electrophysiology performed on mouse brain slices. We expect d3-morphine to induce 
weaker G-protein recruitment, cAMP production and/or neuron hyperpolarization, which would 
explain its lower analgesic effect. We expect to submit the resulting article during summer 2018. 
 
 
Additional comment:  according to the editor comment and the instructions to authors about stats, 
all significant p values were replaced by p<0.05  throughout the manuscript in order to avoid the 
use of multiple P values.  
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Reviewer 1 comments to Author 
 
The authors report an experiment on an important issue - that of tracking metabolic activity of 
opioids over chronic treatment. While I understand that the goal is to pick up activity from the 
most recent injection rather than that of previous injections, I am a bit concerned with the 
methodology constituting "chronic use". Morphine has a relatively short half-life, and thus I 
wonder if it would have been more appropriate to inject several times throughout the day rather 
than just once in the morning as I am not convinced that this latter paradigm produces true 
tolerance. While this is an important control for the study, it also doesn't represent the clinical 
picture of chronic use. I am not sure how this would be done to still maintain the nature of the 
study, i.e. detecting metabolism from the most recent injection, but I think it is an important 
consideration for future studies. I think that in a revision, this should be noted in the limitations. 
Also, just a note re: the unexplored hypothesis of upregulation & overproduction of central M3G, 
Arout et al. (2014) showed M3G activity to be unrelated to morphine hyperalgesia, though this 
coincides with the author's conclusion. 
 
Answer:  
- As noticed by the reviewer, the magnitude of tolerance can vary depending on the route of 
administration and continuous morphine administration produces greater tolerance compared to 
repeated injections of morphine (Morgan & Christie, 2011). However, in the literature, a major part 
of morphine analgesic tolerance studies performed on mice involves repeated administration of 
morphine (2259 articles vs 269 articles for morphine pellets and tolerance; source: Web of Science). 
To be more consistent with most of the previous studies, we have chosen to use chronic morphine 
injections rather than pellet implants. We now provide, in the main text, two examples of protocols: 
(1) Ueda & colleagues (cited 114 times) that used a protocol 10 mg/kg once a day during six days 
(Ueda, Yamaguchi, Tokuyama, Inoue, Nishi & Takeshima, 1997) and (2) a study by Elhabazi & 
coll. published in JoVE in 2014 (Elhabazi, Ayachi, Ilien & Simonin, 2014), which described in 
detail a typical morphine tolerance protocol using repeated injections (Elhabazi, Ayachi, Ilien & 
Simonin, 2014; Madia, Dighe, Sirohi, Walker & Yoburn, 2009). Our 9 day long protocol has been 
chosen to allow a potential up regulation of morphine metabolism that might only partially reflect 
morphine-induced tolerance in human. Worthy of note, we did perform similar experiments with 
twice daily morphine injections (10 mg/kg i.p.) and did not observe any difference with the results 
reported in the present study (i.e. complete analgesic tolerance was observed by day 9 on the hot 
plate test, and no upregulation of morphine glucuronidation was observed in tolerant mice). 
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- Human morphine half-life in blood ranged between 2 and 15 h (Berkowitz, 1976; 
Hasselstrom & Sawe, 1993) whereas in mice, morphine half-life in the blood ranged between 20 
and 55 min depending on the experimental model (Dalesio et al., 2016; Webster, Shuster & 
Eleftheriou, 1976). Because morphine only slowly crosses the blood-brain barrier, the time point of 
90 min has been chosen in our experiment to allow a sufficient amount of morphine to reach the 
brain and to be metabolized into M3G. Together with the fact that morphine is either acutely or 
continuously administered in humans, we now alert the reader that, in general, mouse tolerance 
models do not reflect fully the clinical use of chronic morphine.  
 
Specific sentences were added to the discussion to address these limitations and the 
relevance of the tolerance model we used. 
 
Page 16, paragraph 3, line 4: 
“One limitation of our study is the fact that we assessed morphine metabolism at a single time point 
and in the whole brain. (…).” 
   
Page 17, paragraph 1, line 4: 
 “Furthermore, while our tolerance induction protocol is widely accepted in the literature (Elhabazi, 
Ayachi, Ilien & Simonin, 2014; Ueda, Yamaguchi, Tokuyama, Inoue, Nishi & Takeshima, 1997), it 
does not accurately reflect the morphine treatment schedule in patients. Thus, our study’s clinical 
relevance could benefit from using extended release morphine formulations or from increasing the 
number of injections per day. In the latter case, we observed identical results when injecting mice 
twice per day with 10 mg/kg (data not shown).” 
 
 
Reviewer 2 comments to Author 
In this work, the authors report their studies on the kinetics of morphine metabolism upon 
repeated treatment using a deuterated analogue of morphine. Although this is an interesting 
study, it lacks the degree of novelty claimed by the authors. Utilization of a stable labeled 
isotopologue of a drug molecules has been employed frequently in the study of drugs in vivo (for 
a review: Applications of stable isotopes in clinical pharmacology (2011) BJCP 72, 879‐897. This 
review includes approximately 50 examples between the years 1975‐2010) and assessment of the 
effect of chronic dosing on the PK of a drug molecules has also been reported previously for 
antiepileptic drugs (Malik, S.I. et al. Pediatr. Neurol. (2003), 29, 376‐380). The authors report the 
results of a collection of various experiments in a rather confusing and non‐coherent way. 
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Therefore, it is the reviewer’s opinion that the manuscript is not suitable for publication in the 
Journal in its current form and may be reconsidered for publication provided that the previous 
work on stable labelled drugs is clearly described and cited, and the manuscript is rearranged so 
that only the relevant experiments are presented in a logical order in a clear manner. Some 
specific comments are listed below for authors’ consideration. 
 
Answer: We fully agree with this major criticism, and we thank the reviewer for providing key 
articles that have informed our point of view. These insightful comments and recommendations led 
us to improve the content and clarity of the manuscript. Accordingly, we have clearly cited previous 
works on stable isotope labelled-drugs in both introduction and discussion sections. Also, based on 
reviewer’s advice, the manuscript has been extensively rearranged. Hence, the introduction is now 
mainly focused on morphine metabolism, and only the relevant experiments are presented in the 
results section. We have taken into account all suggestions, and both the text and corresponding 
figures have been modified accordingly.  
 
Page 5, paragraph 3, line 5: “Molecules labelled with stable isotopes have been used for decades, 
in both animals and humans, to study drug pharmacokinetic differences induced by chronic 
treatments (for review: (Mutlib, 2008; Schellekens, Stellaard, Woerdenbag, Frijlink & Kosterink, 
2011). As an example, in neonates under maintenance therapy, labelled phenobarbital and 
phenytoin were used to determine clearance, half-life and volume of distribution of the drugs 
without interference with the ongoing therapy (Malik, Painter, Venkataramanan & Alvin, 2003).” 
 
 
Example :Page 16, paragraph 2, line 3: “Our protocol was adapted from previous 
pharmacological studies using stable isotopes (Malik, Painter, Venkataramanan & Alvin, 2003). We 
show that intrinsic differences in stable isotope-labelled drug metabolism and pharmacological 
properties compared to the native drugs do not preclude their use as metabolic probes.” 
 
 
Comment 1. On page 5, 2nd paragraph: The authors state that: “…presence of stable‐isotope 
labeled atoms may dramatically affect cellular uptake and bioavailability profiles through, for 
example, altered membrane permeability and/or access to the catalytic site”. Although kinetic 
isotope effects having (due to alteration of the bond breaking energy) an impact on the 
pharmacokinetics of a drug molecule is well‐documented, only minimum if any impact is 
expected in vivo with respect to other properties of the drug molecule including the potency of the 
physicochemical properties of the drug is minimally affected by the introduction of a stable label 
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(e.g. slight change in lipophilicity by the introduction of deuterium atoms). Therefore, it is not 
obvious to the reviewer how a stable‐isotope label can “alter membrane permeability” and or 
distribution of the drug in vivo. The mechanistic/physicochemical reasons for expecting such a 
change should be explained clearly and a reference to such a phenomena should be provided if 
any. 
 
Answer 1: Please see the answer to comment #13 that proposes a global explanation for the 
metabolic difference between morphine and d3-morphine. 
 
As discussed in the review of Timmins, replacement of hydrogen with deuterium may lead 
to significant alterations of drug metabolism and cause changes in the biological effects of drugs, 
including altered metabolism, pharmacokinetics, and toxicity profiles (Timmins, 2014). Such a 
change is termed kinetic isotope effect (KIE; for review (Atkins & de Paula, 2006; Guengerich, 
2017)). In the case of d3-morphine [(5a, 6a)-7,8-didehydro-4,5-epoxy-17-(methyl-d3) morphinane-
3,6-diol], a reduction in the rate of oxidative N-demethylation and a weakening of the binding to the 
enzyme active center have been decribed in vitro (Elison, Rapoport, Laursen & Elliott, 1961). In 
vivo examples of this phenomenon include a Concert phase I clinical trial, which has shown that the 
deuterated version of paroxetine induces less metabolic inhibition of CYP2D6 (Sanderson, 2009a; 
Sanderson, 2009b). 
Concerning a modulation of BBB permeability, Dewar & colleagues have studied the effect 
of deuterium substitution on the penetration of beta-phenylethylhydrazine into the rat brain. The 
concentration of deuterated beta-phenylethylhydrazine transported into the brain was significantly 
increased compared to its non-deuterated counterpart (Dewar, Dyck, Durden & Boulton, 1988; 
Timmins, 2014). However, no specific mechanism has been proposed so far to explain such 
properties; it can be potentially explained by a modified affinity/efficiency between deuterated and 
non-deuterated compounds for a specific BBB transporter. 
 
Specific sentences and the corresponding references are now included in the discussion.  
 
Page 15, 1nd Paragraph, Line 1 : “Different studies have described important differences in the 
metabolism of various drugs in vitro and in vivo (Mutlib, 2008; Sanderson, 2009a; Schellekens, 
Stellaard, Woerdenbag, Frijlink & Kosterink, 2011). Replacement of hydrogen with deuterium may 
lead to significant alterations of drug metabolism and cause changes in the biological effects of 
drugs, including altered metabolism, pharmacokinetics, and toxicity profiles (Timmins, 2014). Such 
changes are called kinetic isotope effects (KIE; for review (Atkins & de Paula, 2006; Guengerich, 
2017)).” 
 
Page 16, 2nd Paragraph, Line 6 : “For instance, Dewar & colleagues have shown an increased 
penetration of deuterated beta-phenylethylhydrazine into the rat brain compared to non-deuterated 
beta-phenylethylhydrazine (Dewar et al., 1988; Timmins, 2014). This might be explained by a 
differential affinity between deuterated and non-deuterated compounds for specific BBB 
transporters.” 
 
 
Comment 2. On page 7: It is stated that “…both groups received a final injection of 10 mg/kg of 
morphine (50% or 85%)”. It should be clarified what the percentage numbers refer to. 
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Answer 2: The percentage of d3-morphine is now clarified since we now only present the results for 
the 85% morphine / 15% d3-morphine conditions. Fig 1f and 1g have been removed for more 
clarity. 
Page 7 Paragraph 1, Line 2: “On the ninth day, both groups received a final injection of 10mg/kg 
of morphine (85%) and d3-morphine (15%, w/w; Fig. 1a).”  
 
 
Comment 3. On page 10: “mobile phase” should be used instead of “Buffer”. 
 
Answer 3: “Mobile phase” is now used all along the manuscript. 
 
 
Comment 4. On page 11: It is stated that “Average accuracy values across all sample types for 
morphine…”. It should be clarified what is meant by “average accuracy values” and how these 
numbers are calculated. 
 
Answer 4: The wording of this sentence has been clarified and the definition of accuracy in this 
context has been added. Accuracy values were calculated for each analyte in each sample type by 
spiking naive mouse samples (in triplicate) with known amounts of the analytes and dividing the 
recovered amount by the theoretical amount. Then, for each analyte, accuracy values in the plasma, 
liver, urine, brain and spinal cord were averaged, hence the confusing wording "Average accuracy 
values". To make it easier to understand, this sentence now reads "Accuracy values" instead of 
"Average accuracy values across all sample types".  
 
Page 12, 1st paragraph, line 6- “Accuracy values (defined as the measured amount of analyte 
versus the theoretical added amount in spiked naive samples) for morphine, d3-morphine, M3G and 
d3-M3G were respectively 118±14%, 119±15%, 93±5% and 96±5%.” 
 
 
Comment 5. Figure 1 combines metabolic schemes, study design as well as results from various 
experiments. It should be divided into different figures in alignment with different experiments, 
and more details have to be included in figure legends so that it is clear what is represented by 
data points. 
 
Answer 5: The previous/old figure 1 has now been split in Fig. 1 and Fig. 2 to clearly separate 
“study design” and “results”. Legends have been modified accordingly and now describe in details 
the different panels. Particularly, panels f and g have been removed for more clarity (see below). 
 
 
Comment 6a: On page 12: it is stated that “d3‐M3G formation was significantly decreased by 
38% compared to M3G”. Incorporation of a table into the main part of the manuscript including 
the amounts of morphine and metabolites in different experiments together with the standard 
deviations may be useful as the differences are not clearly visible in the figures due to large 
variations among different animals (assuming that individual points represent different animals 
which should be clarified in the figure legend).  
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Answer 6a: Table 2 now provides the amounts of morphine, d3-morphine and metabolites in 
different tissues together with the standard errors. 
 
 
Comment 6b: Also as the amounts of d3 and “native” morphine are comparable, it is not clear 
how the decrease in M3G formation with the d3 isotopologue can be accounted for based on the 
conservation of mass principle (unless other morphine metabolites are discussed and taken into 
account).  
 
Answer 6b: 
  
i. Does d3-morphine excess account for the decrease in d3-M3G formation? 
 
In old Fig. 1b and 1c (which have been removed from the manuscript but are reproduced below 
along with numerical values in a table), we injected a 50/50% mix of morphine and d3-morphine to 
mice.  
 
D3‐Morphine  Morphine  d3‐M3G  M3G  M3G/Morphine  d3‐M3G/d3‐morphine 
19.5 ± 4.1 15.7 ± 3.8 6.7 ±1.6 10.8 ± 2.4 0.82 ± 0.13  0.41 ± 0.07 (*) 
 
Legend: Liver morphine, d3-morphine and metabolites after injection of a 50%/50% mixture of 
morphine/d3-morphine to mice (sacrifice at t+90mn, n=10, data expressed as mean pmol/mg 
protein ± SEM). *, p<0.05 vs M3G/morphine, Mann-Whitney U test. 
   
As mentioned by the reviewer, liver d3-M3G was reported as significantly lower than M3G (panel 
c): accordingly, one would expect d3-morphine content to be significantly higher compared to 
morphine based on mass conservation. This was not the case for two reasons: 
- First, after re-examination of the data, we found that the difference between M3G and d3-
M3G liver content is actually not significant (p-value: 0.1). Data reported on this figure are 
accurate, but it was a mistake to label it significant. 
- While the absolute amounts of d3-morphine vs morphine (panel b) and d3-M3G vs M3G 
(panel c) are not significantly different, the metabolic ratios (M3G/morphine vs d3-M3G/d3-
morphine, see table) are indeed significantly different. The reason for this is that metabolic 
ratios are calculated for each animal individually and therefore greatly reduce variability.  
 
Based on this, the point of the reviewer still stands: if there is a reduction in d3-M3G formation, d3-
morphine content should be higher than morphine. For the most part, this is actually true. See below 
a table with the numerical values from panels b and c (average ±SEM in pmol/mg protein, n=10). 
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When comparing the decrease in liver d3-M3G formation to the increase of liver d3-morphine, we 
find that d3-morphine increase accounts for ~92% of d3-M3G reduction (3.7 ± 0.6 pmol/mg 
increase in d3-morphine vs 4.08 ± 0.9 pmol/mg decrease in d3-M3G).  
 
D3‐Morphine 
pmol/mg 
Morphine
pmol/mg 
(D3‐morphine)  — (Morphine)
pmol/mg 
d3‐M3G
pmol/mg
M3G 
pmol/mg 
(D3‐M3G) — (M3G)
pmol/mg 
19.5 ± 4.1 15.7 ± 3.8 3.7 ± 0.6  6.7 ±1.6 10.8 ± 2.4 -4.08 ± 0.9 
 
Therefore, we believe mass conservation is largely respected by our data.  
 
ii. Are there differences between morphine and d3-morphine minor metabolites production? 
 
To be thorough, we have also investigated whether there might be a difference in the 
production of minor metabolites. We investigated the presence of normorphine, 6-acetyl-morphine, 
morphine-6-glucuronide, morphine-di-3,6-glucuronide and hydromorphone for which we have pure 
standards to use as reference for retention time and MS transitions.  
Because those metabolites are present in low concentrations, they were impossible to 
quantify in the samples of our original cohort. For that reason, we used a new cohort of mice and 
analyzed urine samples after injection of either 7.5 mg/kg morphine or 7.5 mg/kg d3-
morphine. (The reason we chose 7.5 mg/kg instead of 10 mg/kg morphine is because this cohort of 
mice was used to measure the difference in analgesia between morphine and d3-morphine for 
publication in another article, and we needed a dose that produced < 100% analgesia on the hot 
plate test).  
Urine has been chosen because it contains the highest amount of metabolites following 
morphine injection. Again, a reduction of d3-M3G formation was observed and the d3-M3G/d3-
morphine metabolic ratio was significantly lower than the M3G/morphine metabolic ratio. 
Only normorphine and 6-acetyl-morphine were above the limit of quantification (LOQ). 
Normorphine was present in the urine of morphine-injected mice (0.69±0.11 nmol/ml) while d3-
normorphine was below the limit of detection. This result was expected and is in agreement with 
the study of Elison et al. (1961). Interestingly, d3-6-acetyl-morphine (11 ± 2.5pmol/ml) was present 
only after d3-morphine injection, whereas 6-acetyl-morphine was not detected.  
Regardless, as only low amounts of these minor metabolites were present relative to 
M3G and d3-M3G, they do not significantly impact mass conservation calculations. 
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morphine 
(nmol/ml) 
M3G 
(nmol/ml)
M3G/morphine  
Metabolic ratio 
normorphine 
(nmol/ml)  
6-acetyl-morphine 
(pmol/ml)  
Morphine  
treatment 
(7.5 mg/kg, 
n=7 mice) 
76 ± 12 458 ± 60 6.5 ± 0.6 0.69 ± 0.11 ND (< 5 pmol/ml) 
         
 
d3-morphine 
(nmol/ml) 
d3-M3G 
(nmol/ml)
d3-M3G/d3-morphine 
Metabolic ratio 
d3-normorphine 
(nmol/ml) 
d3-6-acetyl-morphine
(pmol/ml)  
D3-morphine  
treatment 
(7.5 mg/kg, 
n=8 mice) 
114 ± 18 400 ± 70 3.6 ± 0.4 (*) ND  (< 30 pmol/mL) 11 ± 2.5 
          
Expanded Supplementary Table 2 - Quantification of morphine, M3G, normorphine, 6-acetyl-
morphine and respective d3-labelled analogs in mouse urine after injection of morphine or d3-
morphine (7.5 mg/kg, i.p.). Morphine-3,6-diglucuronide and d3-morphine-3,6-diglucuronide were 
not detected (< 50 pmol/mL). Data expressed as mean ± SEM, n= 7 or 8. *, p<0.05, Mann-Whitney 
U-test. ND, not detected. 
 
Comment 6c: Finally, it is not clear to the reviewer by which mechanism incorporation of d3 on 
the N‐methyl group will have an impact on the glucuronidation taking place on the 3‐ position of 
morphine.  
 
Answer 6c: Please see the answer to comment #13 that gives a global explanation. 
 
 
Comment 7. In Figure 1f and g (assuming that each point represents an individual animal), it is 
shown that the extent of glucuronidation is virtually identical for d3‐ and proteo morphine which 
clearly contradicts the claims of the authors based on the results shown in Figure 1c, d and e 
(“thus, it is likely that d3‐M3G formation is decreased in vivo and in vitro compared to native 
M3G…”). This mismatch should be discussed and the impact of the results shown in Figure 1c,d, 
and e should be put into context clearly. 
 
Answer 7: Old Fig. 1f and Fig. 1g have been removed in our revision in order to improve the clarity 
of our manuscript (see next question). Also, panel numbering has been modified in the manuscript. 
However, the old Fig. 1 has been reproduced below to answer the question without confusion. Note 
that the data discussed here was already discussed in answer to comment 6b-i. 
 Careful examination of the panel 1f (reproduced below) indicates that in the case of 
50%/50% mix, liver d3-morphine is slightly higher than liver morphine for each animal. On the 
other hand, liver d3-M3G is consistently lower than liver M3G for those same animals (Fig. 1g: 
note the difference in x and y axis scales).  
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Therefore, we believe panels 1f-1g are consistent both with the data of Fig. 1b-1c 
(corresponding data in histogram form) and with results obtained in BV-2 cultures (Fig 1d) as well 
as glucuronidation assay results (Fig. 1e). 
 
 
Original Fig. 1 reproduced- Requirements and method validation.  LC-MS/MS quantification 
of (b) morphine and d3-morphine and (c) their respective metabolites M3G and d3-M3G in the 
liver of control mice following a single injection of a 50%/50% mix of morphine and d3-morphine 
(m/m, 10 mg/kg i.p.). Data expressed as mean ± SEM; n = 10; Mann-Whitney U test. *, p<0.05. 
(d) LC-MS/MS quantification of M3G and d3-M3G present in the culture medium of BV-2 cells 
incubated with 20 µM of morphine or d3-morphine for 48 h. Data expressed as mean ± SEM; 
n = 6 per group; Mann-Whitney U test. **, p<0.01. (e) Michaelis–Menten kinetics of M3G and 
d3-M3G formation from morphine and d3-morphine respectively using liver extracts of control 
mice. Correlation between (f) d3-morphine and morphine and (g) d3-M3G and M3G levels in the 
liver of control mice in the case of an injected 50%/50% mix of morphine/d3-morphine (m/m, 10 
mg/kg i.p.). Spearman’s r, p-value and R2 of the linear regression fit are indicated in each panel; 
n=10.  
 
 
Comment 8. To the best of the understanding of the reviewer, the results shown in Figure 1h and 
1i comes from experiments identical to the ones shown in Figures 1f and 1g except for a change 
in the ratio of proteo morphine to d3‐morphine. It is not clear to the reviewer why the same 
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experiment was repeated with a different ratio resulting in the use of 10 more animals without 
any good justification. Based on the reasoning stated in the manuscript ( “… to ensure both an 
acceptable level of antinoception and reliable quantification of d3‐morphine and its metabolite 
d3‐M3G.”), the 50%/50% experiment seems to be redundant. 
 
Answer 8: For the clarity of the manuscript and to avoid the redudancy pointed out by the reviewer, 
the Fig. 1f and 1g have been removed and the manuscript has been modified accordingly. Now, 
only results from the animals injected with 85% morphine/15% d3-morphine are presented (see 
below Revised Fig. 1). 
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Revised Fig. 1- Method validation. (a) Structures of morphine, M3G and their respective d3-
labelled counterparts. (b) Metabolic ratios for M3G/morphine and d3-M3G/d3-morphine in the 
urine of mice having a single injection of morphine or d3-morphine (7.5 mg/kg, i.p.). Data 
expressed as mean ± SEM; n = 7 or 8 per group; Mann-Whitney U test. *, p<0.05. (c) Michaelis–
Menten kinetics of M3G and d3-M3G formation from morphine and d3-morphine respectively 
using liver extracts of control mice. Correlation between (d) d3-morphine and morphine, and 
between (e) d3-M3G and M3G levels in the liver of control mice after injection of a mix of 
morphine/d3-morphine (85%/15%, m/m, 10 mg/kg, i.p.).  
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Comment 9. On page 13, 3rd paragraph: it is stated that “In the brain, morphine and M3G 
content were found to be similar in chronically treated animals compared to control mice”. This 
observation argues strongly against a possible change in the metabolism of morphine upon 
chronic administration and questions the reasoning of this whole study. In case the reviewer is 
missing a key point, the authors should clarify their interpretation of this experiment. 
 
Answer: The quoted observation was not made before the study was undertaken, but is the actual 
result of the study. Indeed, morphine metabolic processes in the CNS are poorly characterized and 
their potential alteration on a morphine long-term treatment inducing tolerance had never been 
studied. Whether or not morphine chronic treatment affected in vivo morphine metabolism in brain 
and BBB permeability was a major pending question. An upregulation of central morphine 
catabolism and overproduction of the pro-algesic and pro-inflammatory M3G (Lewis et al., 2010; 
Roeckel, Le Coz, Gaveriaux-Ruff & Simonin, 2016) represented an important hypothesis to test. 
However, no adaptive process has been observed in tolerant mice and our initial hypothesis was 
therefore disproved.  
 
 
Comment 10. At some parts of the manuscript “chronically treated” and “tolerant” are used 
interchangeably. Even though this is accurate, to use only “chronically treated” may help with 
clarification. 
 
Answer 10: “chronically treated” and “tolerant” have been now used when  appropriated. 
 
 
Comment 11. Once again to the best of the understanding of the reviewer, results shown in 
Figure 1b suggests that glucuronidation of d3‐morphine takes place to a lower extent than the 
proteo analogue. However, results shown in Figure 1d contradicts this finding as for each 
individual animal there is no difference in terms of extent of glucuronidation between proteo and 
deutero analogues (the reviewer assumes the plot of ratios (M3G/morphine) should give a similar 
plot). These seemingly contradictory results should be discussed in detail. 
 
Answer 11: We apologize for the confusion but original Fig. 1b and 1d show completely different 
sets of data (see reproduced original Fig. 1 in answer to comment #7). Fig 1b shows liver 
content of morphine and d3-morphine after an injection of 50%/50% mix of morphine/d3-
morphine. It goes in pair with Fig. 1c which shows metabolites amounts for the same animals and 
in which we can observe reduced liver d3-M3G content compared to M3G. 
On the other hand, the data presented in Fig. 1d is from a completely different experiment as 
we were using BV-2 cells in culture. This experiment shows that for an identical dose added to the 
medium, glucuronidation extent is lower in the case of d3-morphine. 
Therefore, we believe the results from those panels are consistent since all animals had 
lower amounts of d3-M3G than M3G and this effect was also seen in BV-2 cultures. 
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To avoid any confusion, panels b and c from the former figure have been removed in our 
revised manuscript as we have chosen to only focus on the injection ratio 15%/85% (see revised 
Fig. 1 reproduced in answer #8). Former panel d showing results in BV-2 cultures has also been 
removed and data from the BV-2 experiment is now reported as a sentence in the text instead. This 
was done to avoid confusing the reader between data from cultures and data from mice. 
 
Page 12, paragraph 1, line 3: “First, we used microglial cells able to convert morphine into M3G 
(Togna et al.,2013). The murine microglial BV-2 cell line was incubated with morphine or d3-
morphine (20 µM, 48 h). LC-MS/MS analysis revealed a significant decrease of d3-M3G formation 
in vitro by 22% compared to M3G (183±10 vs 236±13 pmol/mg protein, n=6, p<0.05, Mann-
Whitney U-test).” 
 
 
Comment 12. Figure 3a shows a decrease in d3‐M3G amount in tolerant mice. If this observation 
is a real observation then this should reflect on the ratio as well since the d3‐morphine levels are 
unchanged. This discrepancy makes the interpretation of the data extremely difficult. 
 
Answer 12: We agree with this comment. Even if a trend was visible on the ratio corresponding to 
spinal cord (old Fig. 3a reproduced below, right panel), our statistical analysis does not find any 
significant ratio-difference even if a there is a statistical difference between the amount of d3-M3G 
in control and chronically treated animals.  
 
This discrepancy led us to take a conservative stance and to conclude that spinal 
glucuronidation in control and tolerant animals was not actually different, especially since results 
from all other fluids and tissues consistently show no difference in glucuronidation between control 
and chronically treated mice. Data from the spinal cord induce confusion as pointed out by the 
reviewer and have therefore been removed from the manuscript as we do not believe they show a 
convincing effect. 
 
 
Comment 13. On page 15: It is stated that “the impact of deuteration … on catabolic processes is 
highly dependent on the localization of the deuterium atoms the closer to the site targeted by 
catabolic enzymes, the stronger the alteration”. This statement should be explained 
mechanistically at a molecular level since based on knowledge on kinetic deuterium isotope 
Page 14 of 60
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
effects it is not clear to the reviewer how the substitution of the N‐methyl hydrogens with 
deuterium will have an effect on the bond breaking energy of the O‐H hydrogen at the C3 
position. 
 
Answer 13: Kinetic isotope effect (KIE) studies focusing on P450s have shown an important impact 
of deuterium on CYP (mainly via a primary kinetic isotope effects; for review (Atkins & de Paula, 
2006; Guengerich, 2017)). However, no data are available on the impact of deuterated compounds 
and therefore their position on UGT activity. Furthermore, the current understanding of substrate-
UGT interactions is very limited. Indeed, while the interaction between UGT enzymes and the sugar 
donor UDPGA are well characterized (involving the C-terminal domain of UGT), the interaction 
between the substrate aglycone (e.g. morphine) and the N-terminal domain of the UGT is poorly 
described (Wu, Kulkarni, Basu, Zhang & Hu, 2011). Because of the lack of structural information, 
the molecular understanding of this UGT-morphine interaction and activity remains limited. The 3 
deuterium atoms located on the N17-methyl group of morphine were not expected to influence the 
glucuronidation step involving the C3-OH because these two groups are at opposite ends of the 
morphine skeleton. The impact of morphine N-methyl deuteration on UGT activity is therefore a 
secondary kinetic isotope effect (SKIE; because no bond to the deuterium substituted atom is 
broken or involved in a modification (Atkins & de Paula, 2006)). SKIEs are usually much smaller 
than primary kinetic isotope effects and are largely determined by the vibrations of the carbon-
deuterium bond (Westaway, 2006). In our case, the SKIE due to deuteration of the N17-methyl 
group  revealed a major implication of that moiety into UGT catalytic activity. While it may seem 
counterintuitive at first, a study of UGT2B7-morphine interactions by (Coffman, Kearney, 
Goldsmith, Knosp & Tephly, 2003) provides plausible structural arguments to explain this 
phenomenon. Indeed, it was shown that binding of morphine to the N-terminus of UGT2B7 
involves a pocket made of amino acids 96 to 101. Amino acid 99 (Asp) was critical for morphine 
binding to UGT2B7, and this binding is predicted to occur between Asp99 and the morphine 
nitrogen. See below annotated Fig. 7A from the Coffman et al. study. 
 
Legend: Annotated Fig. 7A from Coffman et al. (2003) showing morphine binding to UGT2B7 
through interaction between morphine nitrogen and Asp99. 
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Additional structural studies (i.e. crystallography) are required to fully understand how the 
morphine nitrogen interacts with the Asp99 of the N-terminal domain of the UGT. Unfortunately, 
we do not have the technical expertise to explore this question further. However, since the crucial 
amino acid for morphine binding interacts with the nitrogen, it seems plausible that alteration of the 
N-methyl group (e.g. triple deuteration) would affect this binding and therefore glucuronidation 
activity. Furthermore, the fact that d3-morphine is surprisingly much less analgesic than native 
morphine (see (Elison, Rapoport, Laursen & Elliott, 1961) and our answer to the Editor, question 
iii) suggests that N-methyl deuteration affects morphine pharmacology to a stronger extent than 
what is usually seen with deuterated drugs.  
Specific sentences have been added to the manuscript to propose an explanation for reduced 
glucuronidation of d3-morphine.  
Page 15, paragraph 1, line 8: “However, no data is currently available on the impact of 
deuteration on drug glucuronidation by UGT enzymes. Because of the lack of a crystal structure of 
the UGT N-terminal domain, which is the region involved in substrate binding, our current 
understanding of UGT-morphine interactions and activity remains limited (Wu, Kulkarni, Basu, 
Zhang & Hu, 2011). The 3 deuterium atoms located on the N17-methyl group of morphine were not 
expected to influence the glucuronidation step involving the C3-OH because these two groups are at 
opposite ends of the morphine skeleton (Fig. 1a).                                                                                                    
Therefore, the impact of deuteration of the N-methyl on glucuronidation is a secondary kinetic 
isotope effect (SKIE), because no bond to the deuterium substituted atom is broken or involved in a 
modification (Atkins & de Paula, 2006). SKIEs are usually much smaller than primary kinetic 
isotope effects and are largely determined by the vibrations of the carbon-deuterium bond 
(Westaway, 2006). In our case, the SKIE due to deuteration of the N17-methyl group revealed a 
major implication of that moiety into UGT catalytic activity. While it may seem counterintuitive at 
first, a study of UGT2B7-morphine interactions (Coffman, Kearney, Goldsmith, Knosp & Tephly, 
2003) provides plausible structural arguments to explain this phenomenon. Indeed, it was shown 
that binding of morphine to the N-terminus of UGT2B7 involves a pocket made of amino acids 96 
to 101. Amino acid 99 (Asp) was critical for morphine binding to UGT2B7, which was predicted to 
occur between Asp99 and the morphine nitrogen. Additional structural studies (i.e. crystallography) 
are required to fully understand how the morphine N17 interacts with the Asp99 of the N-terminal 
domain of the UGT. However, since the crucial amino acid for morphine binding interacts with the 
nitrogen, it seems plausible that alteration of the N-methyl group (e.g. triple deuteration) would 
affect this binding and therefore glucuronidation activity. Furthermore, the fact that d3-morphine is 
surprisingly much less analgesic than native morphine (Elison, Rapoport, Laursen & Elliott, 1961) 
suggests that N-methyl deuteration affects morphine pharmacology to a stronger extent than what is 
usually seen with deuterated drugs. Overall, this shows the importance of assessing the impact of 
stable isotope-labelling on drug pharmacology in metabolism studies using such drugs.” 
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Comment 14. Drug drug interaction studies mentioned on page 16 that “…often rely on 
indirect assays of metabolic adaptations with probe substrates” is used to assess the induction 
potential of a test drug on another drug metabolized by a certain enzymatic route. The 
methodology proposed by the authors can be useful only to study the autoinduction potential 
of the administered drug. 
 
Answer 14: We agree that our methodology is useful to study the metabolic auto-induction of the 
administered drug. However, we believe that it also allows to determine a potential adaptation of 
the BBB. 
 
 
Comment 15. On page 17, there is a speculation around “…potential alteration of other 
metabolizing enzymes such as sulfotransferases and CYP3A4”. This statement should be 
clarified in the context of morphine metabolism in the spinal cord assuming this speculation is 
related to the possible changes in the extent of morphine metabolites in the spinal cord. 
 
Answer 15: We agree with the review r and this highly speculative sentence has been removed 
from the main text along with data from the spinal cord (see answer to comment #12). 
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ABSTRACT 
Background and Purpose- Chronic administration of medication can have an important impact on 
metabolic enzymes leading to physiological adaptations. Morphine metabolism in the liver has been 
extensively studied following acute morphine treatment but morphine metabolic processes in the 
central nervous system are poorly characterised. Long-term morphine treatment is limited by the 
development of tolerance, resulting in a decrease of its analgesic effect. Whether or not morphine 
analgesic tolerance affects in vivo brain morphine metabolism and blood-brain barrier (BBB) 
permeability remains a major pending question. Thus, our aim was to characterise the in vivo 
metabolism and BBB permeability of morphine after long-term treatment at both central and 
peripheral levels. 
Experimental Approach- Mice were injected with morphine or saline solution for 8 consecutive 
days in order to induce morphine analgesic tolerance. On the ninth day, both groups received a final 
injection of morphine (85%) and d3-morphine (morphine bearing three 
2
H; 15%, w/w). Mice were 
then euthanized and blood, urine, brain and liver samples were collected. LC-MS/MS was used to 
quantify morphine, its metabolite morphine-3-glucuronide (M3G) and their respective d3-labelled 
counterparts.  
Key Results and conclusions- We found no significant differences in morphine CNS uptake and 
metabolism between control and tolerant mice. This suggests that morphine analgesic tolerance is 
not linked to an increase of morphine glucuronidation into M3G or an alteration of the drug’s global 
BBB permeability. Interestingly, d3-morphine metabolism was decreased compared to morphine without 
any interference with our study.  
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KEYWORDS- Deuterated morphine, stable isotope, metabolism, mass spectrometry, blood-brain 
barrier, morphine, morphine-3-glucuronide, UGT, morphine tolerance, mouse. 
 
ABBREVIATIONS - ACN, acetonitrile; BBB, blood-brain barrier; CID, collision gas; CNS, 
central nervous system; d3-morphine, morphine bearing three 
2
H; LC-MS/MS, liquid 
chromatography coupled to tandem mass spectrometry; LOD, limit of detection; MS, mass 
spectrometry; LOQ, limit of quantification; M3G, morphine-3-glucuronide; M6G, morphine-6-
glucuronide; MOR, mu opioid receptor; MPE, maximal possible effect; MRM, multiple reaction 
monitoring mode; KIE, kinetic isotope effect; SKIE, secondary kinetic isotope effect; UGT, UDP-
glucuronosyl-transferase. 
 
INTRODUCTION  
Chronic administration of medication (Sweeney & Bromilow, 2006) such as anticancer drugs (Hu, 
Mackenzie, Lu, Meech & McKinnon, 2015), pain killers (codeine (Antonilli et al., 2012)), 
antibiotics (rifampin (Lee et al., 2006)) or antiepileptic drugs (phenobarbital (Sakakibara, Katoh, 
Kondo & Nadai, 2016)) can crucially impact metabolic enzymes and ultimately lead to 
physiological adaptations. Among painkillers, opiate metabolism in the liver has been extensively 
studied following acute morphine treatment (Chau et al., 2014; Smith, 2009). Although morphine’s 
analgesic effect mainly involves central binding to the mu type of opioid receptors (MORs), its 
metabolism in the central nervous system (CNS) is poorly characterised (Laux-Biehlmann, 
Mouheiche, Veriepe & Goumon, 2013). Previous studies have demonstrated how long-term 
administration results in tolerance, i.e. a decrease in the analgesic effect of morphine (Williams et 
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al., 2013). While progress has been made towards understanding the cellular basis of morphine 
analgesic tolerance (Williams et al., 2013), whether it affects in vivo morphine blood-brain barrier 
(BBB) permeability and CNS metabolism remains a major pending question (Chaves, Remiao, 
Cisterninoa & Decleves, 2017; Strazza et al., 2016; Yousif et al., 2008). Intriguingly, naloxone still 
induces hyperalgesia and precipitates withdrawal symptoms in both tolerant and dependent animals 
and patients (Morgan & Christie, 2011). This implies that a pool of MORs remains functional in 
such states. Thus, the possibility that chronic morphine treatment leads to tolerance through 
upregulation of central morphine catabolism and overproduction of its pro-algesic and pro-
inflammatory metabolite morphine-3-glucuronide (M3G) (Lewis et al., 2010; Roeckel, Le Coz, 
Gaveriaux-Ruff & Simonin, 2016) represents an interesting hypothesis. 
The major route of morphine metabolism is glucuronidation and relies on the UDP-glucuronosyl-
transferase (UGT) family of enzymes expressed in hepatocytes (Stone, Mackenzie, Galetin, 
Houston & Miners, 2003), neurons and glial cells of the CNS (King, Rios, Assouline & Tephly, 
1999). In mice, UGT2B36 mainly converts morphine to M3G whereas morphine-6-glucuronide 
(M6G) is absent (Kuo, Hanioka, Hoshikawa, Oguri & Yoshimura, 1991; Milne, Nation & Somogyi, 
1996; Oguri, Hanioka & Yoshimura, 1990; Xie et al., 2016; Zelcer et al., 2005). 
Monitoring morphine metabolism in chronic treatments represents a challenge due to the residual 
presence of precursors or metabolites from previous administrations (Rubovitch, Pick & Sarne, 
2009). Chronic administration of a drug can also change drug pharmacokinetics. Furthermore, 
alterations of brain metabolism cannot be distinguished from peripheral metabolism or a change in 
blood-brain barrier (BBB) permeability. Molecules labelled with stable isotopes have been used for 
decades, in both animals and humans, to study drug pharmacokinetic differences induced by 
chronic treatments (for review: (Mutlib, 2008; Schellekens, Stellaard, Woerdenbag, Frijlink & 
Kosterink, 2011). As an example, in neonates under maintenance therapy, labelled phenobarbital 
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and phenytoin were used to determine clearance, half-life and volume of distribution of the drugs 
without interference with the ongoing therapy (Malik, Painter, Venkataramanan & Alvin, 2003).  
The present study uses stable isotope-labelled morphine to study morphine BBB permeability and 
metabolism after morphine chronic treatment. We show that morphine analgesic tolerance is not 
linked to metabolic changes or alterations in the drug’s overall blood-brain barrier permeability.  
 
METHODS 
Animals 
Experiments were performed with 45 day-old adult male C57BL/6 mice weighing 24 ± 3g 
(Charles River, L’Arbresle, France). Animals were given free access to food and water, with a 12h 
light–dark cycle at a temperature of 22°C ± 2°C. All procedures were performed in accordance with 
European directives (86/609/EEC) and were approved by the regional ethics committee and the 
French Ministry of Agriculture (license No. 00456.02 to Y.G.). All intraperitoneal (i.p.) injections 
of morphine and d3-morphine were performed in the morning (light phase at 10AM). 
 
Acute Morphine and d3-Morphine Injection 
Mice were weighed and then i.p. injected with 7.5 mg/kg morphine (Euromedex, 
Souffelweyersheim, France) or pure d3-morphine ((5a, 6a)-7,8-didehydro-4,5-epoxy-17-(methyl-
d3) morphinane-3,6-diol; Alsachim, Illkirch Graffenstaden, France) diluted in NaCl 0.9% (w/v). 
Urine was collected 90 min later. 
 
Tolerance Induction and d3-Morphine Injection 
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Mice were injected (i.p.) with 10 mg/kg of morphine diluted in NaCl 0.9% (w/v), or an equivalent 
volume of saline for 8 consecutive days (Singh, Jain & Kulkarni, 2003). On the ninth day, both 
groups received a final injection of 10mg/kg of morphine (85%) and d3-morphine (15%, w/w; Fig. 
1a). Because our objectives were to determine if morphine central glucuronidation and BBB 
permeability were affected, mice were euthanised 90 min after d3-injection and their blood, urine, 
brain and liver were immediately collected. This 90 min time point has been chosen because it 
represents a good compromise between morphine’s half life in the blood and in the CNS of mice 
(Dalesio et al., 2016; Webster, Shuster & Eleftheriou, 1976; Xie, Bouw & Hammarlund-Udenaes, 
2000). 
 
Nociception Assays 
Tolerance development was assessed every day 30 min after each injection. Mice were placed on a 
hot plate (Bioseb, Vitrolles, France) set at 54°C for the measurement of heat nociceptive responses. 
Latency before the first sign of hind paw discomfort (hind paw licking or jumping) was recorded 
with a 30 s cut-off. Prior to morphine or saline injections, a baseline response latency was obtained 
for each mouse. Data are expressed as % maximal possible effect (% MPE) according to the 
following formula: 
%	 =
(	
		) − (
		 	)
( − 		) − (
				)
× 100 
 
Plasma and Urine Recovery 
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Plasma was prepared from blood recovered in lithium-heparin tubes (BD, ref 367526) by 
centrifugation at 1,300g for 15 min. Urine was collected into low-binding microtubes (Sorenson, 
SafeSeal, ref 27210) . 
 
Cell Culture and Treatment 
The mouse BV-2 microglial cell line was maintained in RPMI 1640 medium (Thermo Fisher 
Scientific, Illkirch Graffenstaden, France) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Thermo Fisher Scientific) and antibiotics (penicillin 100 U/ml, streptomycin 100 
µg/ml; Thermo Fisher Scientific) at 37°C under a humidified atmosphere with 5% CO2.  
BV-2 cells (10
6
) were seeded in 6 cm diameter culture dish for 24 h in presence of FBS. Then, the 
medium was replaced with 3ml of fresh medium containing 20 µM of morphine in the absence of 
FBS. Conditioned medium was recovered after 48 h for extraction and LC-MS/MS analysis. 
 
Preparation of Tissues and Fluids 
Brain and liver were homogenised with an Ultra Turrax instrument (Ika, Staufen, Germany) in 1 
ml and 5 ml of H2O, respectively, containing protease inhibitors (cOmplete Mini, EDTA-free, 
Roche, Basel, Switzerland). The homogenates were then sonicated (2 times 10 s, 90W) with a Vibra 
Cell apparatus (Sonics, Newtown, U.S.A.) and centrifuged (14,000g, 30 min) at 4°C. Supernatant 
was recovered and protein concentration determined using the Bradford method (Protein Assay, 
Bio-Rad, Marnes-la-Coquette, France). In order to quantify opiates in the brain and liver, 100 µl of 
tissue extract, plasma or BV2-conditioned media were acidified with 700 µl of 0.5% formic acid 
(v/v). After centrifugation (14,000g, 15 min, 4°C), supernatants were collected prior to solid phase 
extraction (SPE). The SPE procedure was performed with a positive pressure manifold (Thermo 
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Electron, Courtaboeuf, France). HyperSep PGC SPE-cartridges (1 cc, 25 mg, Thermo Electron) 
were first activated with 1 ml of acetonitrile (ACN) and then washed twice with 1 ml of H2O / 
formic acid 0.1% (v/v) and samples were loaded on SPE-cartridges. Cartridges were dried for 1 min 
under vacuum, and were washed with 1 ml of H2O / formic acid 0.1% (v/v). Pre-elution was 
performed with 1 ml of ACN 2% / H2O 97.9% / formic acid 0.1% (v/v/v). Elution was performed 
with 800 µl of ACN 20% / H2O 79.9% / formic acid 0.1% (v/v/v). Eluates were collected in low 
binding 1.5 ml tubes and centrifuged (14,000g, 10 min, 4°C). Supernatants were dried under 
vacuum and resuspended in 100 µl of H2O / formic acid 0.1% (v/v) prior to MS analysis (see 
below). Urine (10 µl) was diluted with H2O / formic acid 0.1% (v/v) by a factor of 100 prior to 
direct LC-MS/MS (liquid chromatography coupled to tandem mass spectrometry) analysis. For 
brain, liver and plasma samples, a volume of 10 µl was injected on the HPLC column; for urine, 5 
µl of the diluted samples were injected. 
 
Enzymatic Activity Assay 
250 µg of liver extracts were used to perform morphine glucuronidation enzymatic assays. First, 
extracts were incubated for 30 min at 4°C in the presence of alamethicin (50µg/mg of protein; 
Sigma Aldrich) adjusted to a final volume of 112 µl with H2O. Then, the enzymatic reaction was 
performed in 100 mM phosphate buffer (pH 7.4), 4 mM MgCl2, and increasing concentrations of 
morphine or d3-morphine (0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 2, 4 and 6 mM) in a final 
volume of 200 µl at 37°C for 32 min. After 5 min of equilibration at 37°C, the reaction was started 
by the addition of UDPGA to a final concentration of 5 mM. Reactions were terminated by 
precipitation with perchloric acid (0.7% final concentration, v/v). Samples were centrifuged 
(20,000g, 15 min, 4°C). Supernatants were collected and 10 µl of supernatant were directly 
analysed by LC-MS/MS. 
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Km and Vmax were obtained from a Michaelis-Menten representation after a nonlinear curve fit 
with the least-squares method using Graphpad Prism 6 software. 
 
LC-MS/MS Instrumentation and Analytical Conditions 
Analyses were performed on a Dionex Ultimate 3000 HPLC system (Thermo Scientific, San Jose, 
USA) coupled with a triple quadrupole Endura mass spectrometer (Thermo Scientific). The system 
was controlled by Xcalibur v. 2.0 software (Thermo Electron). Samples were loaded onto an 
Accucore C18 RP-MS column (ref 17626-102130; 100 x 2.1 mm 2.6 µm, Thermo Scientific) heated 
at 40°C. The presence of morphine, d3-morphine and corresponding 3-O-glucuronides was studied 
using the multiple reaction monitoring mode (MRM). Elution was performed at a flow rate of 400 
µl/min by applying a linear gradient of mobile phases A/B. Mobile phase A corresponded to ACN 
1% / H2O 98.9% / formic acid 0.1% (v/v/v), whereas mobile phase B was ACN 99.9% / formic acid 
0.1% (v/v). The gradient used is detailed in Table 1.  
Electrospray ionization was achieved in the positive mode with the spray voltage set at 3,750 V. 
Nitrogen was used as the nebulizer gas and the ionization source was heated to 250°C. Desolvation 
(nitrogen) sheath gas was set to 45 Arb and Aux gas was set to 15 Arb. The Ion transfer tube was 
heated at 350°C. Q1 and Q2 resolutions were set at 0.7 FWHM, whereas collision gas (CID, argon) 
was set to 2 mTorr. Identification of the compounds was based on precursor ion, selective fragment 
ions and retention times obtained for morphine, M3G, d3-morphine (Alsachim) and d3-M3G 
standards (Lipomed, Arlesheim, Swiss). Selection of the monitored transitions and optimization of 
collision energy and RF Lens parameters were manually determined (see Table 1 for details). 
Qualification and quantification were performed in MRM mode. Quantification was obtained using 
Quan Browser software (Thermo Scientific). For tissues and fluids, alkaloids were quantified using 
calibration curves of external standards (morphine, M3G, d3-morphine and d3-M3G; 1 fmol to 100 
Page 29 of 60
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
11 
 
pmol/injection) added to urine, plasma, brain, and liver extract of naive mice and submitted to the 
same procedure described for respective fluids and tissue recovery. Limits of detection (LOD) for 
morphine, d3-morphine, M3G and d3-M3G were typically around 1-50 fmol, depending on the 
nature of the matrix (Supplementary Table 1). LOD was defined as the lowest detectable amount 
of analyte with a signal-to-noise (S/N) ratio > 3. Limit of quantification (LOQ) was defined as the 
lowest detectable amount of analyte with a signal-to-noise (S/N) ratio > 10 (Supplementary Table 
1).  All amounts of opiates measured in samples fit within the standard curve limits, with typical 
analytical ranges (the range of amounts that can be accurately quantified) from 1 fmol – 100 pmol 
to 150 fmol – 100 pmol. Recoveries (extraction efficiency) for morphine, d3-morphine, M3G and 
d3-M3G were respectively 30±7%, 31±8%, 93±5% and 96±5%. Accuracy values (defined as the 
measured amount of analyte versus the theoretical added amount in spiked naive samples) for 
morphine, d3-morphine, M3G and d3-M3G were respectively 118±14%, 119±15%, 93±5% and 
96±5%. Precision (CV% between repeated injections of the same sample) values were <1% for 
same-day measurements and <5% for inter-day measurements.  
 
Statistics 
 Statistical analysis was performed using Graphpad Prism 6 software. Groups were compared 
using the Mann-Whitney U test. A p-value <0.05 was considered statistically significant. 
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RESULTS 
Methodology validation 
We have compared, in vitro, the glucuronidation of native and d3-morphine (Fig. 1a; morphine 
bearing three 
2
H, resulting in a mass excess of 3 Da compared to the parent drug) into M3G and d3-
M3G, respectively. First, we used microglial cells able to convert morphine into M3G (Togna et al., 
2013). The murine microglial BV-2 cell line was incubated with morphine or d3-morphine (20 µM, 
48 h). LC-MS/MS analysis revealed a significant decrease of d3-M3G formation in vitro by 22% 
compared to M3G (183±10 vs 236±13 pmol/mg protein, n=6, p<0.05, Mann-Whitney U-test). A 
similar result was also observed in vivo in mouse urine after acute injection of morphine or d3-
morphine. Urine d3-M3G was significantly lower than M3G (400±70 vs 458±60 nmol/ml) while 
d3-morphine was higher than morphine (114±18 vs 76±12 nmol/ml) despite both groups receiving 
an equal dose of the parent drug (7.5 mg/kg, i.p.; Supplementary Table 2). Accordingly, the 
metabolic ratio of d3-M3G/d3-morphine was almost reduced by half compared to M3G/morphine 
(Fig. 1b and Supplementary Table 2, p<0.05, Mann-Whitney U-test). 
In vitro experiments performed on control mice liver extracts revealed a Vmax of 2775 pmol/mg 
protein/min and a Km of 0.54 mM for morphine glucuronidation, while d3-morphine 
glucuronidation exhibited a Vmax of 1172 pmol/mg protein/min and a Km of 0.76 mM (Fig. 1c). 
Thus, it is likely that d3-M3G formation is decreased in vitro and in vivo compared to native M3G, 
at least in part due to altered enzyme kinetics.  
As a substitution of deuterium for the N-methyl hydrogens of morphine (Fig. 1a) decreases its 
analgesic effect almost by half (Elison, Rapoport, Laursen & Elliott, 1961), we chose for our 
following in vivo experiments to use a mix of morphine/d3-morphine (85%/15%, w/w, 10 mg/kg 
i.p.) to ensure both an acceptable level of antinociception in mice and reliable quantification of d3-
morphine and its metabolite d3-M3G. After i.p. administration of this mixture to mice, remarkable 
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correlations between liver morphine and d3-morphine (Fig. 1d) as well as between M3G and d3-
M3G were obtained (Fig. 1e). This clearly shows that, despite reduced d3-morphine 
glucuronidation compared to morphine (Fig. 1b, see also metabolic ratios in Table 2 and 
Supplementary Fig. 1a), individual variations in morphine metabolism are accurately reflected by 
d3-morphine metabolism. Therefore, we conclude that (i) d3-morphine can be used to quantify 
newly produced d3-M3G and that (ii) a 85%/15% ratio of morphine/d3-morphine can be used to 
study morphine glucuronidation and CNS uptake alterations in vivo. 
We then determined if chronic morphine treatment for 8 days alters in vivo morphine metabolism 
(Fig. 2a). The hot plate test was used to monitor the onset of morphine analgesic tolerance 30 min 
after injection. On the ninth day, a mix of morphine and d3-morphine (85%/15% w/w, 10 mg/kg 
i.p.) was injected and animals were euthanised 90 min later. 15% of d3-morphine affects only 
weakly morphine-induced analgesia. Indeed, morphine-naive animals reached 71±10% MPE 
following injection of this mix on day 9 (Fig. 2b) whereas naive mice injected with pure morphine 
reached 100% of MPE. Regardless of whether they were injected with 100% morphine or a 
15%/85% mix of d3-morphine and morphine on day 9, morphine-tolerant animals returned to 
% MPE values similar to naïve saline-treated mice. 
 
Morphine glucuronidation and brain uptake in tolerant mice 
With this protocol, morphine and M3G amounts found in tolerant mice may include morphine and 
M3G resulting from previous injections (days 1 to 8) (Rubovitch, Pick & Sarne, 2009) while d3-
morphine and d3-M3G levels reflect only CNS uptake and catabolism due to the last injection (day 
9). Therefore, only results for d3-labelled molecules will be discussed in detail. Full quantification 
data for all four compounds are available in Table 2. Since d3-morphine is injected on the last day, 
it should be noted that quantification of morphine, M3G, d3-morphine and d3-M3G in mice relies 
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on external standard calibration curves, since no internal standards for absolute quantification are 
available. We were unable to detect any M6G in our experiments as mice are known to convert 
morphine into M3G but not M6G (Kuo, Hanioka, Hoshikawa, Oguri & Yoshimura, 1991; Milne, 
Nation & Somogyi, 1996; Oguri, Hanioka & Yoshimura, 1990; Xie et al., 2016; Zelcer et al., 2005). 
In the brain, morphine and M3G contents were found to be similar in chronically treated animals 
compared to control mice (Mann-Whitney U test, p>0.05). De novo synthesis of d3-M3G, 
corresponding solely to d3-morphine glucuronidation on day 9, was not modified in tolerant 
animals compared to naive mice receiving only morphine/d3-morphine on the last day. 
Accordingly, the brain metabolic ratio (d3-M3G/d3-morphine) was similar in control and tolerant 
animals (Fig. 3a and Table 2). As expected, d3-morphine glucuronidation was reduced in the brain 
of control and tolerant mice, as reflected by the reduced d3-M3G/d3-morphine ratios compared to 
M3G/morphine ratios (Fig. 3b and Table 2). However, as seen with the liver in our validation study 
(Fig. 1d and 1e), there were remarkable correlations between brain morphine and d3-morphine 
levels (Fig. 3c) and between M3G and d3-M3G contents in control and tolerant animals (Fig. 3d). 
Together, these results demonstrate that analgesic tolerance is not associated with an upregulation 
of brain morphine glucuronidation. The presence of similar amounts of d3-morphine in the brain of 
naive and tolerant mice also shows that morphine BBB permeability is not globally altered.  
In order to determine if morphine glucuronidation was modified at the peripheral level, we have 
analyzed liver tissues (Fig. 4a), plasma (Fig. 4b) and urine (Fig. 4c) of control and tolerant mice. 
Briefly, neither d3-morphine nor d3-M3G levels, nor d3-M3G/d3-morphine metabolic ratios were 
altered in tolerant animals (Fig. 4 and Table 2). Despite reduced glucuronidation of the d3-
morphine compared to native morphine (Supplementary Fig. 1a-c), LC-MS/MS analysis revealed 
again remarkable correlations between morphine and d3-morphine levels (Supplementary Fig. 2a-
c) and between M3G and d3-M3G contents (Supplementary Fig. 3a-c) in the periphery. Together, 
these results demonstrate that peripheral morphine glucuronidation is not affected in tolerant mice. 
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DISCUSSION 
Effect of morphine N-methyl deuteration on glucuronidation activity 
Different studies have described important differences in the metabolism of various drugs in 
vitro and in vivo (Mutlib, 2008; Sanderson, 2009; Schellekens, Stellaard, Woerdenbag, Frijlink & 
Kosterink, 2011). Replacement of hydrogen with deuterium may lead to significant alterations of 
drug metabolism and cause changes in the biological effects of drugs, including altered metabolism, 
pharmacokinetics, and toxicity profiles (Timmins, 2014). Such changes are called kinetic isotope 
effects (KIE; for review (Atkins & de Paula, 2006; Guengerich, 2017)). In the case of d3-morphine, 
a reduction in the rate of oxydative N-demethylation and a weakening of the binding to the enzyme 
active center have been decribed in vitro (Elison, Rapoport, Laursen & Elliott, 1961). However, no 
data is currently available on the impact of deuteration on drug glucuronidation by UGT enzymes. 
Because of the lack of a crystal structure of the UGT N-terminal domain, which is the region 
involved in substrate binding, our current understanding of UGT-morphine interactions and activity 
remains limited. The 3 deuterium atoms located on the N17-methyl group of morphine were not 
expected to influence the glucuronidation step involving the C3-OH because these two groups are at 
opposite ends of the morphine skeleton (Fig. 1a).                                                                                                                                                                                                
Therefore, the impact of deuteration of the N-methyl on glucuronidation is a secondary 
kinetic isotope effect (SKIE), because no bond to the deuterium substituted atom is broken or 
involved in a modification (Atkins & de Paula, 2006). SKIEs are usually much smaller than primary 
kinetic isotope effects and are largely determined by the vibrations of the carbon-deuterium bond 
(Westaway, 2006). In our case, the SKIE due to deuteration of the N17-methyl group revealed a 
major implication of that moiety into UGT catalytic activity. While it may seem counterintuitive at 
first, a study of UGT2B7-morphine interactions (Coffman, Kearney, Goldsmith, Knosp & Tephly, 
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2003) provides plausible structural arguments to explain this phenomenon. Indeed, it was shown 
that binding of morphine to the N-terminus of UGT2B7 involves a pocket made of amino acids 96 
to 101. Amino acid 99 (Asp) was critical for morphine binding to UGT2B7, which was predicted to 
occur between Asp99 and the morphine nitrogen. Additional structural studies (i.e. crystallography) 
are required to fully understand how the morphine N17 interacts with the Asp99 of the N-terminal 
domain of the UGT. However, since the crucial amino acid for morphine binding interacts with the 
nitrogen, it seems plausible that alteration of the N-methyl group (e.g. triple deuteration) would 
affect this binding and therefore glucuronidation activity. Furthermore, the fact that d3-morphine is 
surprisingly much less analgesic than native morphine (Elison, Rapoport, Laursen & Elliott, 1961) 
suggests that N-methyl deuteration affects morphine pharmacology to a stronger extent than what is 
usually seen with deuterated drugs. Overall, this shows the importance of assessing the impact of 
stable isotope labelling on drug pharmacology in metabolism studies using such drugs. 
Deuterated drugs as probes for metabolic studies 
We have used an in vivo methodological approach enabling to monitor CNS stable isotope-
labelled drug uptake and degradation during chronic treatment without interference from ongoing 
drug administration and metabolite presence due to previous injections. Our protocol was adapted 
from previous pharmacological studies using stable isotopes (Malik, Painter, Venkataramanan & 
Alvin, 2003). We show that intrinsic differences in stable isotope-labelled drug metabolism and 
pharmacological properties compared to the native drugs do not preclude their use as metabolic 
probes.  
LC-MS/MS can identify and quantify low amounts of target compounds with a selectivity of >99% 
(Manes, Mann & Nita-Lazar, 2015). It allows the analysis of metabolites of interest following acute 
or chronic treatments and can be easily applied to study the pharmacokinetics of other homeostatic 
and metabolic processes by adding heavier precursors (
2
H, 
13
C…) at defined times. One limitation of 
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our study is the fact that we assessed morphine metabolism at a single time point and in the whole 
brain. However, in vivo longitudinal studies in animals and humans could be achieved using different 
stable isotope-labelled precursors (d3-morphine, d6-morphine…) and periodical MS analysis of 
blood, urine, as well as microdialysis samples. Furthermore, while our tolerance induction protocol is 
widely accepted in the literature (Elhabazi, Ayachi, Ilien & Simonin, 2014; Ueda, Yamaguchi, 
Tokuyama, Inoue, Nishi & Takeshima, 1997), it does not accurately reflect the morphine treatment 
schedule in patients. Thus, our study’s clinical relevance could benefit from using extended release 
morphine formulations or from increasing the number of injections per day. In the latter case, we 
observed identical results when injecting mice twice per day with 10 mg/kg (data not shown).  
In addition to monitoring drug metabolism, our methodology can assess modifications of BBB 
permeability after chronic treatment. No differences of d3-morphine brain content were observed 
between acute and chronic morphine treatments. However, the use of stable isotope-labelled drugs 
needs to be carefully performed because BBB-permeability for the deuterated analog might be 
altered. For instance, Dewar & colleagues have shown an increased penetration of deuterated beta-
phenylethylhydrazine into the rat brain compared to non-deuterated beta-phenylethylhydrazine 
(Dewar, Dyck, Durden & Boulton, 1988; Timmins, 2014). This might be explained by a differential 
affinity between deuterated and non-deuterated compounds for specific BBB transporters. 
Notably, our approach could be useful in therapeutic drug monitoring and drug-drug interaction 
studies, which often rely on indirect assays of metabolic adaptations with probe substrates (Kang & 
Lee, 2009; Sinz, Wallace & Sahi, 2008). Contrary to common practice, this method allows 
improved selectivity by relying on probes very similar to the therapeutic molecule, and could be 
implemented without disturbing ongoing treatment. Finally, stable isotope-labelled drugs could be 
especially useful as probes for in vivo metabolic and BBB permeability alterations in the case of 
therapeutic drugs with extensive half-lives. 
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M3G involvement in chronic morphine side effects 
Kinetic parameters obtained on liver extracts (Km of 0.54 mM and Vmax of 2.77 nmol/mg 
protein/min, Fig. 1c) are in agreement with values published in the literature (Km of 0.42 mM and 
Vmax of 19 nmol/mg protein/min (Shiratani, Katoh, Nakajima & Yokoi, 2008)). The lower Vmax 
might be due to the fact that we used liver extracts instead of purified liver microsomes, which are 
enriched with UGT enzymes. Similarly, our data is consistent with previous studies reporting 
morphine and M3G plasma levels (low µM ranges) 90 minutes after morphine injection (Andersen, 
Ripel, Boix, Normann & Morland, 2009; Zelcer et al., 2005). 
Neither morphine CNS uptake nor its glucuronidation were altered in chronically treated animals 
compared to acutely treated mice. This result argues against a role of global M3G overproduction in 
the development of tolerance and hyperalgesia following morphine chronic treatment. However, 
since we used whole brain samples, we cannot rule out local CNS alterations in morphine 
metabolism and uptake. Furthermore, M3G could still play a role in morphine analgesic tolerance 
and hyperalgesia through alterations of its effects at the receptor level (i.e. through TLR4 and MOR 
(Lewis et al., 2010; Roeckel et al., 2017)). Therefore, additional studies focusing on local (e.g. in 
the PAG, which is the main site of morphine analgesia) M3G synthesis and modulation of 
TLR4/MOR signalling are needed to clarify whether or not M3G is involved in morphine tolerance 
and hyperalgesia. 
Previous studies of a potential alteration in BBB function following morphine treatment used 
either in vitro (Strazza et al., 2016) or in vivo approaches (blue Evans-albumin tracer, [
131
I]-
albumine and [
14
C]-sucrose) (Chaves, Remiao, Cisterninoa & Decleves, 2017; Sharma & Ali, 2006; 
Yousif et al., 2008). Contrasting effects have been described (i.e., increase or no increase of BBB 
permeability). Our in vivo approach, which we believe is more physiological than previous studies, 
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suggests that global morphine BBB permeability is not altered and does not play a role in the 
development of negative side effects following chronic morphine. 
 
Conclusions 
We confirmed the importance of deuterated compounds as a means of studying metabolic 
adaptations that follow chronic drug administration. Interestingly, N-methyl deuteration affected 
morphine pharmacology to a stronger extent than what is usually seen with deuterated drugs. This 
highlights the importance of proper kinetic isotope effect characterisation when using stable 
isotope-labelled drugs for pharmacological studies. To our knowledge, no study prior to ours had 
directly investigated morphine uptake and glucuronidation in the CNS of tolerant animals. Using 
d3-morphine in the mouse, we have shown that analgesic tolerance is not linked to an increase in 
morphine glucuronidation into M3G or to a modification of the drug’s global blood-brain barrier 
permeability.  
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 TABLES AND FIGURES LEGENDS 
TABLES  
Table 1- LC and MS conditions for the purification and the detection of morphine, M3G 
and their respective d3-labelled counterparts. Mobile phase A corresponded to ACN 1% / H2O 
98.9% / formic acid 0.1% (v/v/v), whereas mobile phase B was ACN 99.9 % / formic acid 0.1% 
(v/v).  
 
Table 2- Quantification of morphine, M3G, and respective d3-labelled analogs in the brain, 
liver, plasma and urine of control and tolerant mice after injection of a mix of morphine/d3-
morphine (85%/15%, w/w, 10 mg/kg i.p.) on day 9. Data expressed as mean ± SEM, n = 10. *, 
p<0.05 vs M3G/morphine, Mann-Whitney U-test. 
 
FIGURES 
Fig. 1- Method validation. (a) Structures of morphine, M3G and their respective d3-labelled 
counterparts. (b) Metabolic ratios for M3G/morphine and d3-M3G/d3-morphine in the urine of 
mice having a single injection of morphine or d3-morphine (7.5 mg/kg, i.p.). Data expressed as 
mean ± SEM; n = 10 per group; Mann-Whitney U test. *, p<0.05. (c) Michaelis–Menten kinetics of 
M3G and d3-M3G formation from morphine and d3-morphine respectively using liver extracts of 
control mice. Correlation between (d) d3-morphine and morphine, and between (e) d3-M3G and 
M3G levels in the liver of control mice after injection of a mix of morphine/d3-morphine 
(85%/15%, w/w, 10 mg/kg, i.p.).  
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Fig. 2- Tolerance induction protocol. (a) Protocol of morphine tolerance induction across days 
1 to 8 (D1-D8, 10 mg/kg i.p.) and a single injection of 85%/15% morphine/d3-morphine (w/w, 10 
mg/kg i.p.) on day 9. (b) Development of morphine tolerance. Antinociception is expressed as % 
maximum possible effect (% MPE) on the hot plate test observed 30 min after morphine or saline 
injection across days. Values of MPE are expressed as mean ±SEM; n=10 mice per group. 
Fig. 3- Morphine brain uptake and glucuronidation is not altered in tolerant mice. 
Quantification was done in control and morphine-tolerant mice 90 min after a single injection of a 
mix of morphine/d3-morphine (85%/15%, w/w, 10 mg/kg i.p.) on day 9. (a) LC-MS/MS 
quantification of brain d3-morphine and d3-M3G and corresponding metabolic ratios in control and 
tolerant animals. (b) Brain M3G/morphine and d3-M3G/d3-morphine ratios of control and tolerant 
mice. (c) Correlation between brain amounts of d3-morphine and morphine. (d) Correlation 
between brain amounts of d3-M3G and M3G. Spearman’s r, p-value and R
2
 of the linear regression 
fit are indicated in each panel. Each data point represents one animal and is expressed as mean 
±SEM; n = 10 ; Mann-Whitney U test. *, p<0.05. 
 
Fig. 4- Peripheral morphine glucuronidation is not altered in tolerant mice. LC-MS/MS 
quantification of d3-morphine and d3-M3G was done in control and morphine-tolerant mice 90 min 
after a single injection of a mix of morphine/d3-morphine (85%/15%, w/w, 10 mg/kg i.p.) on day 9. 
(a)  Liver. (b) Plasma. (c) Urine. Metabolic ratios correspond to d3-M3G/d3-morphine. Each data 
point represents one animal, data expressed as mean ±SEM; n = 10 for all samples; Mann-Whitney 
U test. 
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HPLC gradient 
Time (min) 0 2.5 4.5 6.5 7.5 8 12 
% B mobile phase 1 1 30 99 99 1 1 
 
MS ionization, selection, fragmentation and identification parameters 
Compound Polarity 
Precursor 
(m/z) 
Product 
(m/z) 
Ion product 
type 
Collision 
Energy (V) 
RF Lens 
(V) 
Morphine Positive 285.98 201.11 Quantification 26.23 183 
Morphine Positive 285.98 165.36 Qualification 40.89 183 
Morphine Positive 285.98 181.06 Qualification 36.24 183 
d3-morphine Positive 288.98 201.06 Quantification 26.48 178 
d3-morphine Positive 288.98 153.13 Qualification 43.16 178 
d3-morphine Positive 288.98 165.04 Qualification 39.02 178 
M3G Positive 462.19 286.11 Quantification 30.02 276 
d3-M3G Positive 465.19 289.17 Quantification 29.92 242 
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Brain (pmol/mg protein) Metabolic ratio 
 
morphine d3-morphine M3G d3-M3G M3G/morphine d3-M3G/d3-morphine 
Control 33 ± 5.8 6.3 ± 1.1 3.7 ± 0.6 0.4 ± 0.07 0.13 ± 0.02 0.07 ± 0.01* 
Tolerant 22 ± 2.3 4.0 ± 0.4 2.8 ± 0.3 0.3 ± 0.03 0.14 ± 0.01 0.08 ± 0.01* 
       Liver (pmol/mg protein) Metabolic ratio 
 
morphine d3-morphine M3G d3-M3G M3G/morphine d3-M3G/d3-morphine 
Control 27 ± 6.4 5.8 ± 1.2 18 ± 4.1 2.0 ± 0.47 0.82 ± 0.13 0.4 ± 0.07* 
Tolerant 27 ± 3.7 5.3 ± 0.7 14 ± 2.3 1.5 ± 0.28 0.59 ± 0.09 0.32 ± 0.05* 
 Plasma (pmol/ml) Metabolic ratio 
 
morphine d3-morphine M3G d3-M3G M3G/morphine d3-M3G/d3-morphine 
Control 1254 ± 401 261 ± 80 1892 ± 406 234 ± 56 2.27 ± 0.42 1.25 ± 0.24 
Tolerant 679 ± 119 129 ± 19 1352 ± 202 162 ± 24 2.66 ± 0.65 1.46 ± 0.26 
 
 
Urine (nmol/ml) Metabolic ratio 
 
morphine d3-morphine M3G d3-M3G M3G/morphine d3-M3G/d3-morphine 
Control 270 ± 72 55 ± 14 954 ± 124 110 ± 14 4.61 ± 0.6 2.53 ± 0.31* 
Tolerant 273 ± 72 56 ± 15 1471 ± 395 174 ± 51 5.49 ± 0.51 2.98 ± 0.26* 
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Fig. 1- Method validation.  
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Fig. 2- Tolerance induction protocol.  
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Fig. 3- Morphine brain uptake and glucuronidation is not altered in tolerant mice.  
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Fig. 4- Quantification of d3-morphine and d3-M3G in tissues and fluids of control and tolerant mice.  
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This PDF file includes: - Supplementary Fig. 1 to 3 and Supplementary Table 1 and 2. 
 
Supplementary figures: 
Supplementary Fig. 1- Metabolic ratios for M3G/morphine and d3-M3G/d3-morphine in 
control and tolerant mice. Quantifications were done in control and morphine-tolerant mice 
treated with a single injection of a mix of morphine/d3-morphine (85%/15%, m/m) on day 9. (a) 
Liver. (b) Plasma. (c) Urine. Data expressed as mean ± SEM; n = 10 for all samples; Mann-Whitney 
U test. *, p<0.05. 
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Supplementary Fig. 2- Correlation between amounts of d3-morphine and morphine in 
tissues and fluids of control and tolerant mice. (a) Liver. (b) Plasma. (c) Urine. Spearman’s r, p-
value and R2 of the linear regression fit are indicated in each panel; n=10 for all tissues. 
 
Supplementary Fig. 3- Correlation between amounts of d3-M3G and M3G in tissues and 
fluids of control and tolerant mice. (a) Liver. (b) Plasma. (c) Urine. Spearman’s r, p-value and R2 
of the linear regression fit are indicated in each panel; n=10 for all tissues. 
 
Supplementary Tables: 
Supplementary Table 1- Limits of d tection (LOD), limits of quantification (LOQ) and 
reportable ranges for morphine, d3-morphine, M3G and d3-M3G in brain, liver, plasma and 
urine samples. LOD was defined as the lowest detectable amount of analyte with a signal-to-noise 
(S/N) ratio > 3. LOQ was defined as the lowest detectable amount of analyte with a signal-to-noise 
(S/N) ratio > 10. Data are presented as the mean ± SEM of 5 measurements. Reportable range 
reflects the range of analyte amounts that fit within the linear standard curve limits. 
 
Supplementary Table 2- Quantification of morphine, M3G, and respective d3-labelled 
analogs in mouse urine after acute injection of morphine or d3-morphine (7.5 mg/kg, i.p.). Data 
expressed as mean ± SEM. Mann-Whitney’s U-test; *, p<0.05  for the comparison of metabolic 
ratios. 
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Supplementary Figure 1 
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Supplementary Figure 2 
 
 
Control Tolerant
Liver
Plasma
Urine
morphine (pmol/mg protein)
0 20 40 60 80
0
5
10
15
20
r = 0.99
p-value <0.0001
R2=0.98
morphine (pmol/mg protein)
0 20 40 60
0
5
10
15
r = 0.89
p-value 0.0011
R2=0.92
morphine (pmol/ml)
0 1000 2000 3000 4000 5000
0
200
400
600
800
1000
r = 0.99
p-value <0.0001
R2=0.99
morphine (pmol/ml)
0 500 1000 15000
50
100
150
200
250
r = 0.94
p-value 0.0002
R2=0.93
morphine (nmol/ml)
0 200 400 600 800 1000
0
50
100
150
200
r = 1
p-value <0.0001
R2=0.99
morphine (nmol/ml)
0 200 400 600 800 1000
0
50
100
150
200
r = 0.99
p-value <0.0001
R2=1
d3
-m
or
ph
in
e
(p
m
ol
e/
m
g 
pr
ot
ei
n)
d3
-m
or
ph
in
e
(p
m
ol
e/
m
g 
pr
ot
ei
n)
d3
-m
or
ph
in
e
(p
m
ol
e/
m
l)
d3
-m
or
ph
in
e
(p
m
ol
e/
m
l)
d3
-m
or
ph
in
e
(n
m
ol
e/
m
l)
d3
-m
or
ph
in
e
(n
m
ol
e/
m
l)
a
b
c
Page 57 of 60
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
5 
 
Supplementary Figure 3 
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Supplementary Table 1 
  
morphine 
(fmol ± SEM)  
d3-morphine  
(fmol ± SEM) 
M3G  
(fmol ± SEM) 
d3-M3G  
(fmol ± SEM) 
Brain LOD 3.01 ± 1.04 2.17 ± 0,18 2.50 ± 0.13 0.29 ± 0.02 
Brain LOQ 10.02 ± 3.45 4.82 ± 2.43 8.32 ± 0.44 0.98 ± 0.07 
Reportable range 10 fmol - 100 pmol 10 fmol - 100 pmol 10 fmol - 100 pmol 1 fmol - 100 pmol
Liver LOD 27.67 ± 1.24 31.31 ± 8.23 1.86 ± 0.003 2.16 ± 0.31 
Liver LOQ 92.13 ± 4.12 104.26 ± 27.41 6.19 ± 0.01 7.19 ± 1.04 
Reportable range 100 fmol - 100 pmol 150 fmol - 100 pmol 10 fmol - 100 pmol 10 fmol - 100 pmol
Plasma LOD 39.08 ± 11.99 15.20 ± 0.82 2.14 ± 0.29 0.29 ± 0.02 
Plasma LOQ 130.13 ± 39.93 50.61 ± 2.73 7.12 ± 0.98 0.97 ± 0.08 
Reportable range 150 fmol - 100 pmol 100 fmol - 100 pmol 10 fmol - 100 pmol 1 fmol - 100 pmol
Urine LOD 
Urine LOQ 
Reportable range 
0.61 ± 0.09 
2.02 ± 0.29 
10 fmol - 100 pmol 
 
0.45 ± 0.02 
1.62 ± 0.06 
10 fmol - 100 pmol 
 
1.63 ± 0.11 
5.44 ± 0.36 
10 fmol - 100 pmol 
0.32 ± 0.04 
1.06 ± 0.12 
10 fmol - 100 pmol
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Supplementary Table 2 
 
morphine 
(nmol/ml) 
M3G 
(nmol/ml) 
M3G/morphine  
Metabolic ratio 
morphine  
treatment 
(7.5 mg/kg, 
n=7 mice) 
76 ± 12 458 ± 60 6.5 ± 0.6 
 
d3-morphine 
(nmol/ml) 
d3-M3G 
(nmol/ml) 
d3-M3G/d3-morphine 
Metabolic ratio 
d3-morphine  
treatment 
(7.5 mg/kg, 
n=8 mice) 
114 ± 18 400 ± 70 3.6 ± 0.4 (*) 
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